Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

Easdec 2011 programme

EASDEC 2011 Programme
12.30 – 4.45: Screening for Diabetic Retinopathy in Europe - Strategies for Overcoming Hurdles to Progress Organising Committee: Professor Simon Harding, Dr Deborah Broadbent, Dr Kenneth Swa, Professor Elzbieta Bandurska-Stankiewicz 4.45 – 6.00 Novartis symposium: Ranibizumab in DME – new age of treatment Chaired by:Professor Krystina Raczynska and Professor Anne Katrin Sjølie Dr Lipowski: Diabetic macular oedema – epidemiology and social issue Dr Partyka: Diagnostic and current methods of treatment of DME Prof. Malukiewicz: Lucentis in DME - results of clinical studies 7.15 Opening ceremony fol owed by refreshments 9.15 – Introduction and welcome Anne Katrin Sjølie and Elzbieta Bandurska Stankiewicz Session 1: Combined session with the European Hypertension Society
Chairs: Krysztof Narkiewicz and Massimo Porta 9.20 – 9.50: Invited lecture: Roland E Schmieder: Vascular remodel ing of the microcirculation in hypertension and diabetes 9.50 – 10.05: Possible role of angiotensin II receptor blockade in the glucotoxicity on human retinal pericytes. E. Berrone, E. Beltramo, S. Taral o, M. Porta 10.05 – 10.20: Mitochondrial-derived ROS controls MMP2 activity by retinal capil ary pericytes exposed to high glucose. J.M. Tarr, L. Gatti, E.M. Kohner, K. Kaul, A. Datti, A. Orlacchio, R. Chibber 10.20 – 10.35: Fenofibrate effect on diabetic retinopathy. N. Grigoryeva, E. Shklyarov, F. Shadrichev, O. Kryaneva 10.35 – 10.50: Long-term associations between serum lipids and panretinal photocoagulation in type 1 diabetes. J. Grauslund, J S. Jørgensen, A. Green, A K. Sjølie Session 2: Combined session with the European Hypertension Society
11.20 – 11.50: Invited lecture: Enrico Agabiti Rosei: Treatment of hypertensive diabetic patients: the goals and strategies 11.50 – 12.05: The predictive power of microaneurysm count on development of sight threatening retinopathy and the response to treatment with an angiotensin receptor blocker. Results from the DIRECT Programme. A.K. Sjølie for the DIRECT Programme Study Group 12.05 – 12.20: Deterioration of the glomerular filtration rate and high vascular endothelial growth factor level in the eye are seemed to be the markers of diabetic retinopathy progression after cataract surgery. A.G. Kuzmin, D.V. Lipatov, T.A. Chistyakov, O.M. Smirnova, M.I. Arbuzova, A.V. Ilyin, M.V. Shestakova 12.20 – 12.35: Risk factors for diabetic eye complications in short duration (1-10 years) of type 1 diabetes in Warmia and Mazury, Poland. J. Pieczynski, E. Bandurska-Stankiewicz, W. Matuszewski, J. Rutkowska, D. Wiatr-Bykowska 12.35 – 12.50: Blindness and Frequency of Vitrectomy in Young Danish Type 1 Diabetic Patients. A 15-year fol ow-up. R. Broe, B. S. Olsen, J. Grauslund, P. Hougaard, A. K. Sjølie. Winner of the Best Abstract Prize 12.50 – 1.45: Lunch and Exhibition viewing Session 3: Poster session
Chairs: Stela Vujosevic and Grazyna Malukiewcz A new system for screening of diabetic retinopathy in institute for clinical and experimental medicine (IKEM). T. Sosna, R. Svancarova, M. Kahle Changes in vascular diameter after laser treatment in patients with diabetic macular edema. K. Lundberg, A.K. Sjølie, J. Grauslund Diabetes is associated with changes in retinal vessel calibre in women. T. von Hanno, G. Bertelsen, J. Grauslund, A.K. Sjølie, E.B. Mathiesen No difference in prevalence of retinal vein occlusions (RVO) between diabetic and non diabetic participants in The Tromsø Eye Study. G. Bertelsen, M.G. Erke, A.K. Sjølie, I. Njølstad British Ophthalmic Surveil ance Unit (BOSU) study of Progression to Sight Threatening Retinopathy in Pregnancy (STDR). C. Mulhol and, M . Quinn, W. Chan, B. Foot Management and Outcome of Cholesterol Embolus Identified in a Diabetic Retinopathy Screening Programme. K. Whitehouse, P.M. Dodson Does long chain polyunsaturated fatty acids (PUFA) protect against diabetic retinopathy? K. E. Alsbirk, J. H. Seland Diabetic retinopathy prevalence in patients with short duration (1-10 years) of type 1 diabetes in Warmia and Mazury region, Poland. J. Pieczynski, E. Bandurska-Stankiewicz, W. Matuszewski, J. Rutkowska, D. Wiatr-Bykowska Evaluation of the effectiveness of surgical treatment of idiopathic macular holes using optical coherence tomography. M. Gorczyca, S. Zalewski Posterior vitrectomy in the ophthalmology unit of general district hospital in Olsztyn, Poland. J. Pieczynski, E. Bandurska-Stankiewicz, W. Matuszewski Prevalence and incidence of diabetic macular edema in the pediatric population. M. B. Sultan, C. Starita, K. Huang How accurate are photographic surrogate markers used to detect macular oedema in the English National Screening Programme? H.M. Wharton, J.M. Gibson, P.M. Dodson Pre-eclampsia is not a predictor of progression of diabetic retinopathy. M. Lind, A. K. Sjølie Session 4: Risk factors
Chairs: Simon Harding and Elzbieta Bandurska-Stankiewicz 3.10 – 3.30: Deborah Broadbent: Report to Conference: Screening for diabetic retinopathy in Europe/Strategies for overcoming hurdles to progress 3.30 – 3.45: Cardiovascular disease and mortality are related to which vision threatening complication that develops in type 2 diabetic patients. K. Tilma, T. Bek 3.45 – 4.00: Survival analysis of diabetic patients undergoing vitrectomy. G.M.Morphis, T.A. Sandigha, I.A. McKay, D.M. Broadbent, S.P. Harding, H Heimann 4.00 – 4.45: Eva Kohner lecture: Irene Stratton – Does high blood pressure matter in DR? A review of evidence old and new Gala dinner: 7.30 for 8.00 at the Maritime Museum Session 5: Pathophysiology of diabetic retinopathy
9.00 -9.30: Invited lecture: Rafael Simo: Neurodegeneration as an early event of diabetic retinopathy: therapeutic implications 9.30 – 9.45: Retinal Glial Cel s Activation in Diabetics with and without Retinopathy: An in Vivo Study. E. Midena, F. Martini, A. Rediu, M. Casciano, S. Vujosevic 9.45 – 10.00 Diabetic Choroidopathy: A Spectral Domain OCT Study. S. Vujosevic, E. Pilotto, F. Martini, A. Rediu, E. Midena 10.00 – 10.15: Prevalence of diabetic retinopathy and visual impairment in diabetic patients in sub-Saharan Africa. S.P. Harding, S.J. Glover, P.I. Burgess, D.B. Cohen, H.W.C. Hofland, E.E. Zijlstra, T.J. Al ain 10.15 – 10.30: The impact of diabetes on the characteristics of Type 2 Macular Telangiectasia. T. Peto, T.E. Clemons, F.B. Sal o, I. Leung Session 6: Screening and prevention
Chairs: Francesco Bandel o and Krystina Raczynska 11.00 – 11.30: Invited lecture: Jan Taton – Prevention and rehabilitation of significant vision impairment with diabetes mel itus 11.30 – 11.45: Filtering Normal Diabetic Retinopathy Images through Evolutionary Computation. H. L. Tang, T. Peto, J. Goh, Y. Jin, C. Chuluunkhuu 11.45 – 12.00: Late Breaking News Abstract 12.00 – 12.15: Proliferative diabetic retinopathy (R3) referrals from the digital diabetic retinopathy screening program: Urgency of appointment in the hospital eye service achieved and needed? T. K. Geletew, P.M. Amrelia, H.M. Wharton, P.M. Dodson, J.M. Gibson, A. Wright

Source: http://www.easdec.org/userFiles/File/EASDEC2011programme_draft3-3.pdf

Egipto

1. Arquitectura. La La arquitectura egipcia es arquitrabada. Por lo que respecta a la tumba señalar tumba y el templo. su tipología y la evolución de la pirámide desde el modelo escalonado de Zoser, en Sakkara, hasta la Gran Pirámide de Keops, en Gizeh. En cuanto al templo enumerar sus partes y dependencias, y reflejar su evolución desde los edificios al aire libre (Karnak y Luxo

cas.mcmaster.ca

The first thing we need to solve this question is to determine the relative length of amicrosecond. A quick search on the web determines the conversions we need:• 1 day = 24 hours × 60 minutes × 60 seconds = 8.64 ×1010 microseconds• 1 year = 365.25 days ≈ 3.16 × 1013 microsecondsNow if each function takes f (n) microseconds to complete and we wish to find the largestn such that the fu

Copyright © 2010-2014 Drugstore Pdf Search